{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:05:07Z","timestamp":1771563907676,"version":"3.50.1"},"reference-count":25,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"abstract":"<jats:p>The antiviral compound azidothymidine (AZT), alone or in combination with other agents, induces apoptosis in early-passage, Epstein-Barr virus\u2013positive Burkitt lymphoma (EBV+ BL) lines and has clinical activity in EBV+ BL. We report here a mechanism of AZT's antitumor activity. The nuclei of these cells contain activated nuclear factor-\u03baB (NF-\u03baB) subunits p50, c-Rel, RelB, and p52, but not p65. Treatment of primary EBV+ BL lines with AZT inhibited NF-\u03baB within 1 to 2 hours. This was followed by up-regulation of EBV gene expression including viral thymidine kinase (vTK) and apoptosis. Subclones of EBV+ BL cells that demonstrated activated p65 were resistant to AZT. In EBV+ BLs, AZT but not ganciclovir (GCV) was highly phosphorylated to its monophosphate form (AZT-MP). Phosphorylation, as well as apoptosis, was markedly enhanced in the presence of hydroxyurea. AZT inhibits NF-\u03baB and up-regulates EBV gene expression in primary EBV+ BLs. AZT with hydroxyurea may represent an inexpensive, targeted regimen for endemic BL.<\/jats:p>","DOI":"10.1182\/blood-2004-09-3748","type":"journal-article","created":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T20:34:52Z","timestamp":1111696492000},"page":"235-240","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":41,"title":["Azidothymidine inhibits NF-\u03baB and induces Epstein-Barr virus gene expression in Burkitt lymphoma"],"prefix":"10.1182","volume":"106","author":[{"given":"Motoki","family":"Kurokawa","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Medical College, University of Miyazaki, Japan; Departments of Medicine and Microbiology and Immunology, University of Miami School of Medicine, FL: Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, National Cancer Institute\u2013Frederick, MD; and Department of Microbiology and Immunology, The University of North Carolina, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subrata K.","family":"Ghosh","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Medical College, University of Miyazaki, Japan; Departments of Medicine and Microbiology and Immunology, University of Miami School of Medicine, FL: Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, National Cancer Institute\u2013Frederick, MD; and Department of Microbiology and Immunology, The University of North Carolina, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Ramos","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Medical College, University of Miyazaki, Japan; Departments of Medicine and Microbiology and Immunology, University of Miami School of Medicine, FL: Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, National Cancer Institute\u2013Frederick, MD; and Department of Microbiology and Immunology, The University of North Carolina, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul M.","family":"Mian","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Medical College, University of Miyazaki, Japan; Departments of Medicine and Microbiology and Immunology, University of Miami School of Medicine, FL: Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, National Cancer Institute\u2013Frederick, MD; and Department of Microbiology and Immunology, The University of North Carolina, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ngoc L.","family":"Toomey","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Medical College, University of Miyazaki, Japan; Departments of Medicine and Microbiology and Immunology, University of Miami School of Medicine, FL: Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, National Cancer Institute\u2013Frederick, MD; and Department of Microbiology and Immunology, The University of North Carolina, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Cabral","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Medical College, University of Miyazaki, Japan; Departments of Medicine and Microbiology and Immunology, University of Miami School of Medicine, FL: Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, National Cancer Institute\u2013Frederick, MD; and Department of Microbiology and Immunology, The University of North Carolina, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Whitby","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Medical College, University of Miyazaki, Japan; Departments of Medicine and Microbiology and Immunology, University of Miami School of Medicine, FL: Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, National Cancer Institute\u2013Frederick, MD; and Department of Microbiology and Immunology, The University of North Carolina, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen N.","family":"Barber","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Medical College, University of Miyazaki, Japan; Departments of Medicine and Microbiology and Immunology, University of Miami School of Medicine, FL: Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, National Cancer Institute\u2013Frederick, MD; and Department of Microbiology and Immunology, The University of North Carolina, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk P.","family":"Dittmer","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Medical College, University of Miyazaki, Japan; Departments of Medicine and Microbiology and Immunology, University of Miami School of Medicine, FL: Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, National Cancer Institute\u2013Frederick, MD; and Department of Microbiology and Immunology, The University of North Carolina, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"William J.","family":"Harrington","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Medical College, University of Miyazaki, Japan; Departments of Medicine and Microbiology and Immunology, University of Miami School of Medicine, FL: Viral Epidemiology Section, AIDS Vaccine Program, SAIC-Frederick, National Cancer Institute\u2013Frederick, MD; and Department of Microbiology and Immunology, The University of North Carolina, Chapel Hill, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021223361633800_REF1","doi-asserted-by":"crossref","unstructured":"Ghosh SK, Wood C, Boise LH, et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood. 2003;101: 2321-2327.","DOI":"10.1182\/blood-2002-08-2525"},{"key":"2020021223361633800_REF2","doi-asserted-by":"crossref","unstructured":"Toomey NL, Deyev VV, Wood C, et al. Induction of a TRAIL-mediated suicide program by interferon alpha in primary effusion lymphoma. Oncogene. 2001;20: 7029-7040.","DOI":"10.1038\/sj.onc.1204895"},{"key":"2020021223361633800_REF3","doi-asserted-by":"crossref","unstructured":"Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22: 5108-5121.","DOI":"10.1038\/sj.onc.1206556"},{"key":"2020021223361633800_REF4","doi-asserted-by":"crossref","unstructured":"Bellan C, Lazzi S, De Falco G, Nyongo A, Giordano A, Leoncini L. Burkitt's lymphoma: new insights into molecular pathogenesis. J Clin Pathol. 2003;56: 188-192.","DOI":"10.1136\/jcp.56.3.188"},{"key":"2020021223361633800_REF5","doi-asserted-by":"crossref","unstructured":"Xue SA, Labrecque LG, Lu QL, et al. Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer. 2002;99: 635-643.","DOI":"10.1002\/ijc.10372"},{"key":"2020021223361633800_REF6","doi-asserted-by":"crossref","unstructured":"Touitou R, Arbach H, Cochet C, et al. Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines. J Gen Virol. 2003;84: 949-957.","DOI":"10.1099\/vir.0.18687-0"},{"key":"2020021223361633800_REF7","doi-asserted-by":"crossref","unstructured":"Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci U S A. 1997;94: 12592-12597.","DOI":"10.1073\/pnas.94.23.12592"},{"key":"2020021223361633800_REF8","doi-asserted-by":"crossref","unstructured":"Prince S, Keating S, Fielding C, Brennan P, Floettmann E, Rowe M. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. J Virol. 2003;77: 5000-5007.","DOI":"10.1128\/JVI.77.8.5000-5007.2003"},{"key":"2020021223361633800_REF9","doi-asserted-by":"crossref","unstructured":"Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2: 301-310.","DOI":"10.1038\/nrc780"},{"key":"2020021223361633800_REF10","doi-asserted-by":"crossref","unstructured":"Lin A, Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol. 2003;13: 107-114.","DOI":"10.1016\/S1044-579X(02)00128-1"},{"key":"2020021223361633800_REF11","doi-asserted-by":"crossref","unstructured":"Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A. 2000;97: 6055-6060.","DOI":"10.1073\/pnas.100119497"},{"key":"2020021223361633800_REF12","doi-asserted-by":"crossref","unstructured":"Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood. 2000;96: 2537-2542.","DOI":"10.1182\/blood.V96.7.2537"},{"key":"2020021223361633800_REF13","doi-asserted-by":"crossref","unstructured":"Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R. NF-kappaB inhibits gammaherpesvirus lytic replication. J Virol. 2003;77: 8532-8540.","DOI":"10.1128\/JVI.77.15.8532-8540.2003"},{"key":"2020021223361633800_REF14","doi-asserted-by":"crossref","unstructured":"Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP, Faller DV. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol Dis. 1998;24: 114-123.","DOI":"10.1006\/bcmd.1998.0178"},{"key":"2020021223361633800_REF15","unstructured":"Dittmer DP. Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays. Cancer Res. 2003;63: 2010-2015."},{"key":"2020021223361633800_REF16","doi-asserted-by":"crossref","unstructured":"Fakhari FD, Dittmer DP. Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real\u2013time quantitative PCR. J Virol. 2002;76: 6213-6223.","DOI":"10.1128\/JVI.76.12.6213-6223.2002"},{"key":"2020021223361633800_REF17","doi-asserted-by":"crossref","unstructured":"Giacca M, Borella S, Calderazzo F, et al. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3\u2032-azido-3\u2032-deoxythymidine on HIV type 1 infection in vitro. AIDS Res Hum Retroviruses. 1996;12: 677-682.","DOI":"10.1089\/aid.1996.12.677"},{"key":"2020021223361633800_REF18","doi-asserted-by":"crossref","unstructured":"Gustafson EA, Schinazi RF, Fingeroth JD. Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol2000;74: 684-692.","DOI":"10.1128\/JVI.74.2.684-692.2000"},{"key":"2020021223361633800_REF19","doi-asserted-by":"crossref","unstructured":"Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM, Kieff E. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol2004;78: 4108-4119.","DOI":"10.1128\/JVI.78.8.4108-4119.2004"},{"key":"2020021223361633800_REF20","doi-asserted-by":"crossref","unstructured":"Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother. 2001;45: 2082-2091.","DOI":"10.1128\/AAC.45.7.2082-2091.2001"},{"key":"2020021223361633800_REF21","unstructured":"Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 2002;62: 1920-1926."},{"key":"2020021223361633800_REF22","doi-asserted-by":"crossref","unstructured":"Marty R, Ouameur AA, Neault JF, Nafisi S, Tajmir-Riahi HA. AZT-DNA interaction. DNA Cell Biol. 2004;23: 135-140.","DOI":"10.1089\/104454904322964724"},{"key":"2020021223361633800_REF23","doi-asserted-by":"crossref","unstructured":"Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell. 1987;49: 161-170.","DOI":"10.1016\/0092-8674(87)90556-3"},{"key":"2020021223361633800_REF24","doi-asserted-by":"crossref","unstructured":"Jacobs P. The malignant lymphomas in Africa. Hematol Oncol Clin North Am. 1991;5: 953-982.","DOI":"10.1016\/S0889-8588(18)30395-2"},{"key":"2020021223361633800_REF25","doi-asserted-by":"crossref","unstructured":"Spreafico F, Massimino M, Luksch R, et al. Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children. J Clin Oncol. 2002;20: 2783-2788.","DOI":"10.1200\/JCO.2002.08.088"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/1\/235\/1710891\/zh801305000235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/1\/235\/1710891\/zh801305000235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T23:36:27Z","timestamp":1581550587000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/1\/235\/103181\/Azidothymidine-inhibits-NF%CE%BAB-and-induces"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-09-3748","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,1]]}}}